Propanc Biopharma Inc. (PPCB) - Market Cap to Net Income Ratio

Investing in Propanc Biopharma Inc (PPCB) entails high volatility due to a lack of profitability and massive research expenditures, as confirmed by the historical share price performance with the 0.00 indicator. The business relies on developing proenzyme methods to target cancer stem cells to prevent recurrences. However, the structure remains vulnerable due to an extreme dependence on a single technological platform and the risk of clinical trial failure.

PPCB propanc.com: Price to Earnings Ratio in the range 08/16/2025 - 11/10/2026

Comprehensive metric breakdowns and analytics for Propanc Biopharma Inc. (PPCB)

- market price and analyst price targets:

Market Price Propanc Biopharma, Inc.|PPCB - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Propanc Biopharma Inc.|PPCB - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Net Asset Value per Share Propanc Biopharma|PPCB - Company Net Assets|Market Value to Book Value propanc.com|PPCB - Cumulative Company Assets

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

PPCB - Net Income|Future Net Profit Propanc Biopharma Inc|PPCB - P/E Multiple|Projected Price to Earnings Ratio Propanc Biopharma, Inc.|PPCB - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Propanc Biopharma Inc.|PPCB - Operating profit before deduction of amortization|Earnings per share for the trailing year Propanc Biopharma|PPCB - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months propanc.com|PPCB - Earnings growth in current year|Expected earnings per share trend next year Propanc Biopharma Inc

Comprehensive company analysis:propanc.com - PPCB

Finished products of Propanc Biopharma Inc.

The P/E ratio reflects the market value of a single unit of net profit, allowing for an assessment of whether an asset is overvalued or undervalued through the ratio of share price to EPS. By analyzing the forward P/E of Propanc Biopharma Inc (PPCB), an investor can see the projected payback period, which for Propanc Biopharma Inc (PPCB) remains conditional due to the absence of commercial products and reliance on venture financing pending FDA approval.

Key competitors